Silence Therapeutics Begins Exclusive Nasdaq Trading
Silence Therapeutics Begins Exclusive Nasdaq Trading
Silence Therapeutics Begins Exclusive Nasdaq Trading
沉默療法 開始 獨家納斯達克交易
30 November 2021
2021年11月30日
LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the cancellation of admission of its ordinary shares of nominal value £0.05 each (the "Ordinary Shares") to trading on AIM (the "AIM Delisting") was effective from 7:00 a.m. (London time) today.
倫敦，沉默治療公司，納斯達克：SLN(“靜默或“The”公司)是發現、開發和交付新的短幹擾核糖核酸(SiRNA)療法的領先者，用於治療有重大未得到滿足的醫療需求的疾病。該公司今天宣佈，取消其每股面值為GB 0.05的普通股的認購(普通股“)在AIM(The”)上進行交易AIM退市“)已於今日上午7時(倫敦時間)起生效。
Silence's American Depositary Shares, each representing three Ordinary Shares (the "ADSs"), are now listed and only tradeable on the Nasdaq Global Market ("Nasdaq") under the ticker symbol SLN.
沉默的美國存托股份，每股相當於三股普通股(“美國存託憑證)，現已上市，只能在納斯達克全球市場交易(納斯達克“)在股票代碼SLN下。
Mark Rothera, President and Chief Executive Officer of Silence, said: "Listing solely on the Nasdaq supports our strategy to attract high quality U.S. institutional healthcare funds as Silence gears up for the next phase of growth based on maximizing our proprietary mRNAi GOLD™ platform."
沉默公司總裁兼首席執行官馬克·羅瑟拉説：“在沉默公司基於最大限度地利用我們專有的mRNAi黃金™平臺的基礎上，為下一階段的增長做準備，僅在納斯達克上市支持我們吸引高質量美國機構醫療基金的戰略。”
As previously announced, the last day of trading of the Company's Ordinary Shares on AIM was 29 November 2021. Information about the process to deposit Ordinary Shares for delivery of ADSs was provided in the announcement and circular published by the Company on 15 October 2021 and is also available on the Company's website at www.silence-therapeutics.com/investors/AIM-Delisting.
一如先前公佈，本公司普通股於AIM的最後交易日為2021年11月29日。有關繳存普通股以供交付美國存託憑證程序的資料，載於本公司於2021年10月15日刊發的公告及通函，亦可於本公司網站www.silence-therapeutics.com/investors/AIM-Delisting.查閲。
Enquiries:
查詢：
|
Silence Therapeutics plc Gem Hopkins, Head of IR & Corporate Communications |
Tel: +1 (646) 637-3208 |
|
European PR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com |
Tel: +44 (0) 20 3709 5700 |
|
沉默治療公司 吉姆·霍普金斯(Gem Hopkins)，投資者關係和企業公關主管 |
電話：+1(646)637-3208 |
|
歐洲公關 Consilium戰略傳播 瑪麗-簡·埃利奧特/克里斯·威爾士/安吉拉·格雷 郵箱：silenceTreateutics@conconlium-comms.com |
電話：+44(0)2037095700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit .
關於沉默療法
沉默治療公司正在開發新一代藥物，方法是利用人體自然的RNA幹擾(RNAi)機制，抑制特定靶基因的表達，這些基因被認為在具有重大未得到滿足的醫療需求的疾病的病理中發揮作用。Silent公司專有的mRNAi金™平臺可以用來製造精確針對和沉默肝臟中與疾病相關的基因的siRNA，這代表着一個巨大的機會。SILE公司全資擁有的候選產品包括SLN360和SLN124。SLN360旨在滿足在降低天生高水平脂蛋白(A)人羣心血管風險方面的高和普遍的未得到滿足的醫療需求，SLN124旨在解決鐵負荷貧血問題。沉默公司還與阿斯利康公司、美林製藥公司和漢索製藥公司等公司保持着持續的研發合作。有關更多信息，請訪問。
譯文內容由第三人軟體翻譯。